Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)
Release Date:
2026-06-22 11:45
Experimental Background and Objectives
The humanized PBMC-CDX model is an essential tool for in vivo efficacy evaluation of tumor immunotherapy agents. However, significant inter‑donor variability exists in the engraftment efficiency, T‑cell subset differentiation, and the risk of graft‑versus‑host disease (GVHD) among different PBMC donors, which directly impacts model stability and the experimental window.
The objective of this study In the NOG mouse model, we systematically evaluated the in vivo immune reconstitution profiles of multiple PBMC donors and established data-driven donor selection criteria, thereby providing predictable and reproducible cellular resources for tumor immunology research.
Experimental Design
In vivo immune reconstitution dynamics
Data Filtering and Display
1. Human CD45+ cell engraftment rate (hCD45+%)
Key Findings:
G4 achieved the fastest engraftment and the highest peak (reaching 81.3% on Day 22), but was accompanied by severe GVHD.
G1, G5, and G6 have achieved stable reconstruction, with values remaining between 55% and 78% from Day 22 to Day 28, making them suitable for long-term monitoring.
2. Dynamics of T-cell subsets: CD4/CD8 ratio
Key Findings:
G3, G4, G5, and G6 exhibit CD8+ T-cell dominance after Day 22, which is more conducive to studies of anti-tumor immunity.
G1 and G2 maintain a CD4+ predominance, making them suitable for studies of CD4+ T cell–related mechanisms.
GVHD and Animal Tolerance
1. Dynamic (mean) of GVHD scores
2. Changes in Body Weight and Tolerability
G1, G5, G6 : Body weight remained stable or decreased slightly (<10%) prior to Day 28, with good tolerability.
G4 : Day 14—Body weight continued to decline; from Day 22 to Day 28, some animals exhibited a weight loss exceeding 20%, accompanied by high GVHD scores.
G3 : On Day 28, some animals exhibited a marked weight loss, consistent with severe GVHD.
Donor Comprehensive Rating and Recommendation
Donor suitability exhibits substantial interindividual variability: the rate of immune reconstitution, the timing and severity of graft-versus-host disease (GVHD), and the direction of T-cell subset shifts are all strongly correlated with donor characteristics.
High engraftment does not equate to high availability: Although G4 exhibits the highest engraftment rate, severe graft-versus-host disease (GVHD) markedly shortens the experimental window, rendering it unsuitable for long-term studies.
Preferred donor recommendations: G5 (W054K133) and G6 (W054K149) demonstrate the best overall performance in terms of reconstitution efficiency, CD8‑dominant repertoire, and tolerability, making them suitable for tumor immunotherapy efficacy studies.
Hycells Biology Differentiated Advantages of PBMC Preferred Services
Multidimensional in vivo validation: Each batch of PBMCs has been rigorously tested in immunodeficient mice, with comprehensive data provided, including reconstitution curves, GVHD scores, and subpopulation dynamics.
The donor database continues to expand: Covering health donors from multiple countries, providing HLA typing , viral screening, in vitro immunophenotyping, and other background information.
Customized Matching: We recommend the most suitable donor based on the customer’s research needs (long-term vs. short-term, CD4/CD8 preference, and low GVHD risk requirements).
Data transparency and traceability: Provide Streaming raw data , body weight records, GVHD scoring sheets, and medication administration logs, to ensure experimental reproducibility.
For access to the complete experimental report—including raw flow cytometry data, body weight records, GVHD scoring tables, and dosing logs—or for customized donor screening services, please contact the Hycells Biotechnology team.
Related News
With the rapid advancement of cell and gene therapies, the industry is placing increasingly stringent demands on the performance, batch-to-batch consistency, and supply-chain reliability of cell-sorting reagents. At present, the domestic market for sorting magnetic beads remains dominated by imported brands, and their high cost of use and uncertain supply have become significant barriers to both research and industrialization in China.
Recently, Professor Huang He’s team at Zhejiang University published in the top oncology journal “…”. Nature Cancer 》published a research paper titled “Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.” This study is the first to reveal that Serum iron overload By elucidating the key mechanisms by which ferroptosis induces functional exhaustion of CAR‑T cells, we have proposed a targeted approach. ACSL4 Alternatively, a novel strategy involves using the ferroptosis inhibitor Fer-1 to enhance CAR-T cell persistence and antitumor efficacy.
Hycells’s Selected PBMC Reconstruction Data Presentation (Part 2)
HuPBMC model Due to its rapid establishment (3–4 weeks) and ease of use, it has been widely employed for in vivo efficacy evaluation in tumor immunotherapy. However, the conventional model suffers from a critical limitation: the randomness and uncertainty inherent in donor selection. The root of the problem lies not in the model itself, but in the “seed” cells—PBMCs—introduced into the system.
Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)
The humanized PBMC-CDX model is an essential tool for in vivo efficacy evaluation of tumor immunotherapy agents. However, significant inter‑donor variability exists in the engraftment efficiency, T‑cell subset differentiation, and the risk of graft‑versus‑host disease (GVHD) among different PBMC donors, which directly impacts model stability and the experimental window.
A Fresh Start, A New Beginning | Hycells’s Brand Identity Fully Reimagined
Every step forward is aimed at fulfilling our mission even more effectively.
Focused on peptide immunogenicity assessment, precisely empowering tumor neoantigens.
In the field of cancer immunotherapy, tumor neoantigen–specific T-cell responses serve as a key metric for assessing peptide immunogenicity. Leveraging its well-established in vitro assay platform, Hycells Biotechnology offers end-to-end services—ranging from initial screening of peptide immunogenicity and antigen‑specific T-cell expansion to validation of tumor cell‑killing activity—thereby supporting the efficient and reliable discovery and validation of neoantigens.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board